Amgen brought the first DLL3-targeting drug to market earlier this year after it got US approval for bispecific T-cell engager (BiTE) Imdelltra (tarlatamab) for adults with advanced, extensive ...

Finally, in oncology, Amgen is expecting a Phase 3 study readout in the first half of 2025 on Imdelltra a first-in-class treatment for NSCLC. Blincyto is coming off a successful Phase 3 study ...

Amgen reports that in a study of 99 adult patients who had two or more prior treatments, 40 % responded to Imdelltra, meaning their tumor shrank or disappeared.

the latter two acquired via Amgen's ~$28bn deal to acquire Horizon Therapeutics in 2023, alongside gout therapy Krystexxa, and in oncology, Blincyto and Imdelltra (see table above for mechanism of ...

Amgen reported fourth-quarter 2024 adjusted ... up 10% from the year-ago period. Imdelltra (tarlatamab), approved for pre-treated advanced small cell lung cancer (ES-SCLC) in May 2024, recorded ...

Amgen’s product sales are expected to have ... respectively. The U.S. launch of Imdelltra (tarlatamab), approved for pre-treated advanced small cell lung cancer (ES-SCLC) in May 2024, is ...

Amgen successfully launched two next-generation ... Lumakras/Lumykras, Tezspire, Imdelltra, Tavneos and Kanjinti, Mvasi and Amgevita biosimilars. AMGN sits at a Zacks Rank #3 (Hold), holds a ...

Amgen successfully launched two next-generation products ... Lumakras/Lumykras, Tezspire, Imdelltra, Tavneos and Kanjinti, Mvasi and Amgevita biosimilars. AMGN is a Zacks Rank #3 (Hold) stock, with a ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.